Brief: Grand Pharmaceutical Says Phase II Clinical Trial For Ophthalmic Drug Gpn00136 Got Implied Approval From NMPA
18/04/2023 13:52
April 18 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* PHASE II CLINICAL TRIAL APPLICATION IN CHINA OF CO'S
GLOBAL
INNOVATIVE OPHTHALMIC DRUG GPN00136 GOT IMPLIED APPROVAL FROM
NMPA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement